13F Pro quality score
Rank #2,878 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Ernexa Therapeutics Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2024 | 10-K | $582.0K | $-44.5M | — |
| FY 2023 | 10-K | $68.0K | $-21.7M | — |
| FY 2020 | 10-K | $5.8M | $-7.3M | -125.0% |
| FY 2019 | 10-K | $19.8M | $-2.0M | -8.9% |
| FY 2018 | 10-K | $23.3M | $-259.0K | 0.9% |
| FY 2017 | 10-K | $21.3M | $-1.1M | -6.6% |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Ernexa Therapeutics Inc. (ERNA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ERNA at 9.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,878 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Ernexa Therapeutics Inc. reports net income of $-4.0M, free cash flow of $-4.2M. Top institutional holders of ERNA by reported 13-F value include CITADEL ADVISORS, VANGUARD FIDUCIARY, Dauntless Investment Group, based on the most recent SEC filings. ERNA trades on the Nasdaq exchange and files with the SEC under CIK 748592. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ERNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ernexa Therapeutics Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 748592 →